Tag:

Perrigo

Latest Headlines

Latest Headlines

Mylan seeks entry into animal health via $29B bid for Perrigo

When Mylan offered to buy Perrigo for $205 per share last Wednesday, the brewing $29 billion bid was hailed as the giant generics deal Wall Street has been anticipating. But this deal has an animal health angle too: If Mylan pulls it off, the acquisition will mark its entry into the veterinary market.

Will Mylan's $29B bid spur other Perrigo suitors to enter the fray?

More than a couple of analysts agree that there may be a company out there that's after Mylan--and that that could have prompted the company's $28.9 billion bid for Ireland's Perrigo. But now that Mylan's made its offer, could that spur other Perrigo offers, too?

Was Mylan's $29B Perrigo bid a takeover defense? Analysts say yes

Since Mylan went public on Wednesday with a $205-per-share buyout offer for Ireland's Perrigo, analysts have been weighing the pros and cons of a tie-up between the two generics makers. But there's one thing at least a few of them agree on: The $29 billion bid has to be a response to other M&A action going on behind the scenes.

Mylan makes a pass at Perrigo with $205-per-share buyout offer

Generics specialist Mylan has zeroed in on the big buyout everyone's been waiting for. The Pittsburgh-based drugmaker offered $205 per share for Perrigo, the over-the-counter drugmaker that just closed its own $4.5 billion deal for Belgium's Omega Pharma.

UPDATED: Perrigo snaps up OTC specialist Omega in deal worth $4.5B

Perennial dealmaker Perrigo signed on the dotted line for Belgium's Omega Pharma, elbowing past rival bidders to expand its footprint in the global OTC market.  

Deal-hungry Perrigo elbows aside competitors for Omega Pharma

Deal-hungry Perrigo is looking for more seats at the over-the-counter table, and the drugmaker may soon get its wish. The company has entered exclusive talks to acquire Belgian OTC maker Omega Pharma, inching past big-name competitors like Sanofi, Actavis and Boehringer Ingelheim.

Perrigo recalls 367,000 tubes of nicotine lozenges

Smokers often turn to over-the-counter nicotine lozenges to cut their urges when they are trying to quit smoking. It turns out that products made by Perrigo and sold through a whole host of retailers like Wal-Mart and CVS might not work that well.

Bloomberg: Sale of OTC specialist Omega could top $5.3B with bids from Bayer, Sanofi

What's an OTC drugmaker worth in the race to the top of the consumer healthcare space? Potentially more than $5.3 billion, if that drugmaker is Belgium's Omega Pharma.

Pharma peer pressure makes tax-friendly M&A targets the new must-have

Talk about peer pressure. First, a couple of U.S. drugmakers pull off trans-Atlantic deals that shift their official HQs and lower their tax rates. Next, some bigger names go for the same tax-inversion strategy. Now, investors want to know why every drugmaker isn't jumping in.

Dublin-based Perrigo could be up next for a tax-inversion deal

OTC generics maker Perrigo could be the next tax-advantaged company in line for a buyout. And while Perrigo hasn't confirmed any M&A plans, speculation has been enough to send shares soaring.